Introduction
Sudden unexpected death in epilepsy (SUDEP) is the most important directly epilepsy-related cause of death, with an estimated incidence of 1.2 cases per 1000 adult epilepsy patients per year [1] . Some risk factors were identified including longstanding epilepsy and frequent generalized tonic-clonic seizures [1] , but it is still challenging to estimate the individual SUDEP risk. The fatal cascade leading to SUDEP mostly involves primary central apnea following generalized tonicclonic seizures [2] . Although the exact mechanisms of seizure-related apnea are not known, the amygdala appears to play a major role [3] .
Case
An almost 50-year-old patient was admitted to a tertiary epilepsy center for diagnostic procedures. About 3 months before, the patient had suffered from a first and only epileptic seizure. Anticonvulsant treatment had not been started. Mild arterial hypertension was the only known comorbidity.
In the early morning of the first night in the epilepsy center, the patient was found dead in bed in prone position. Subsequent audiovideo-analysis of this night (24-hour-registration on standard epilepsy ward for retrospective semiologic analyses and differential diagnosis; no epilepsy monitoring unit; no EEG-, ECG-, or oxygen-recordings) revealed a nocturnal focal (initial versive movement of the head to the left side) to bilateral tonic-clonic seizure (BTCS), about 1 h prior to the discovery. In analogy to the MORTEMUS study [2] the postictal respiratory rate was assessed by audio-visual inspection of the video registration: after initial hyperpnea of 1.5 min, phases of apneas followed, alternating with phases of pseudo normalization of breath frequency, before a last respiratory sound about 8 min after seizure cessation ( Fig. 1A , Table 1 ).
Previous diagnostic examinations did not reveal clear-cut findings: a routine-EEG recording (20 min) showed slight intermittent frontotemporal slowing ( Fig. 1B ). Furthermore, a second look-analysis of a brain MRI (no epilepsy protocol), performed after the first seizure, showed subtle volume enlargement of right mesial temporal structures (Fig. 1C ). All other examinations were normal (physical examination, laboratory results).
The autopsy in general pathology revealed only findings consistent with a BTCS shortly prior to death, and no other competing cause of death. The neuropathological post-mortem examination revealed circumscribed inflammatory signs in the right amygdala and hippocampus: perivascular lymphocytic infiltrates (CD3-and CD8-positive cells), reactive microglia, and neuronophagia. No antineural autoantibodies were detected in the cerebrospinal fluid. For further details see also Table 1 .
Conclusion
Our case has a number of particularities to be discussed. First, the diagnostic criteria of epilepsy [4] were fulfilled only after the second seizure, which unfortunately led to the patient's death. Second, our patient did not display established risk factors of SUDEP [1] , but suffered from definite SUDEP very early in the disease course. These two facts underscore that a single BTCS is sufficient to trigger the fatal SUDEP cascade even in the absence of chronically altered autonomic function in people with longstanding epilepsies. Thus, it underscores the importance of an early anticonvulsant treatment and suggests that information about SUDEP should be part of the early education for newly diagnosed patients [1] . Also a discussion about patients' safety and the implementation of automatic detection devices in epilepsy centers is urgently needed. Third, neuropathology revealed signs of limbic encephalitis affecting amygdala and hippocampus. Importantly, previous case studies in people with epilepsy demonstrated that electrical stimulation and focal ictal activity of the amygdala and hippocampus lead to suppression of respiratory movements and seizure-related apnea [3] . This link between seizure-related apnea and mesial temporal structures may have facilitated postictal respiratory dysfunction and final SUDEP in our patient.
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